Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "MIT"

6254 News Found

Mitsui Chemicals unveils world’s first device for continuous bile excretion in lab-grown liver cells
Medical Device | April 03, 2026

Mitsui Chemicals unveils world’s first device for continuous bile excretion in lab-grown liver cells

The innovation leverages Mitsui Chemicals’ oxygen-permeable InnoCell cell culture plate to efficiently collect bile while reducing stress on liver cells


AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit
R&D | March 28, 2026

AbbVie stakes claim to redefine skin disease treatment at Global Dermatology Summit

Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims


CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG
News | March 27, 2026

CuraTeQ Biologics enters into agreement with STADA Arzneimittel AG

STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories


LGM Pharma commits $15M to US facilities in major CDMO expansion
News | March 23, 2026

LGM Pharma commits $15M to US facilities in major CDMO expansion

This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing


India tackles rare diseases head-on at landmark summit in New Delhi
News | March 12, 2026

India tackles rare diseases head-on at landmark summit in New Delhi

Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration


Sumitomo Pharma bags world-first go-ahead for iPS cell therapy to treat Parkinson’s disease
News | March 10, 2026

Sumitomo Pharma bags world-first go-ahead for iPS cell therapy to treat Parkinson’s disease

The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%


Bausch Health’s RED-C phase 3 trials fall short, company committed to liver disease research
Clinical Trials | January 29, 2026

Bausch Health’s RED-C phase 3 trials fall short, company committed to liver disease research

The trials, which enrolled over 1,000 patients across 398 sites in 17 countries, showed that the drug was safe and well-tolerated—but ultimately failed to deliver the hoped-for clinical results


IDT and Ansa Biotechnologies join forces to push limits of DNA synthesis
Biotech | January 20, 2026

IDT and Ansa Biotechnologies join forces to push limits of DNA synthesis

The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability


Takeda & Protagonist submit FDA application for groundbreaking polycythemia vera therapy
R&D | January 08, 2026

Takeda & Protagonist submit FDA application for groundbreaking polycythemia vera therapy

The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production


Savara resubmits FDA application for potential treatment in rare lung disease patients
Biopharma | January 01, 2026

Savara resubmits FDA application for potential treatment in rare lung disease patients

The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer